The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abuse potential assessment of cannabidiol (CBD) in recreational polydrug users: A randomized, double-blind, controlled trial
Open accessAbstract
Rationale Treatment with a highly purified oral solution of cannabidiol (CBD), derived from the plant Cannabis sativa L., demonstrated some evidence of central nervous system (CNS)-related adverse events in patients enrolled in phase 3 trials for treatment of childhood-onset epilepsy. Cannabidiol was categorized as a Schedule 1 substance by the United States Drug Enforcement Administration; therefore, it was important to test CBD for human abuse potential. Methods This was a single-dose, randomized, double-blind, double-dummy, placebo- and active-controlled crossover trial. The abuse potential of single oral doses of plant-derived pharmaceutical formulations of highly purified CBD (Epidiolex®; 750 mg, 1500 mg, and 4500 mg) was compared with that of single oral doses of alprazolam (2 mg), dronabinol (10 mg and 30 mg), and placebo in healthy recreational polydrug users. The primary endpoint to assess abuse potential was the maximum effect (E max ) on Drug-Liking visual analog scale (VAS). Other measurements included E max on Overall Drug-Liking VAS, Take Drug Again VAS, positive and negative effects, other subjective effects, and Drug Similarity VAS. Cognitive and psychomotor functions were assessed using the Divided Attention Test, the Hopkins Verbal Learning Test—Revised, and the Digit–Symbol Substitution Task. Pharmacokinetic parameters were determined for CBD and its major metabolites. Standard safety measures and adverse events were assessed. Principal results Of 95 eligible subjects, 43 qualified for the treatment phase, received at least 1 dose of investigational medicinal product, and were included in safety assessments; 35 subjects were included in the pharmacodynamic analysis. Subjects receiving alprazolam and dronabinol had significantly higher Drug-Liking E max ( P < 0.0001) compared with those receiving placebo, confirming study validity. Compared with placebo, Drug-Liking was not significantly different for subjects taking 750-mg CBD ( P = 0.51). Drug-Liking E max values for 1500-mg and 4500-mg CBD were significantly different from placebo ( P = 0.04 and 0.002, respectively); however, the mean differences were <10 points on VAS compared with >18-point differences between positive controls and placebo. Alprazolam and dronabinol had significantly higher Drug-Liking, Overall-Liking, and Take Drug Again VAS E max values compared with all doses of CBD ( P ≤ 0.004). In contrast to alprazolam, CBD administration had no observable effect on cognitive/psychomotor tests. Pharmacokinetic parameters for CBD in this trial were consistent with previous studies. The majority of adverse events reported during the trial were of mild or moderate severity; no serious adverse events or deaths were reported. Conclusion Administration of a therapeutic dose of CBD (750 mg) showed significantly low abuse potential in a highly sensitive population of polydrug users. Although high and supratherapeutic doses of CBD (1500 mg and 4500 mg, respectively) had detectable subjective effects compared with placebo; the effects were significantly lower than those observed with alprazolam and dronabinol.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome
Devinsky, O., Cross, J. H., Laux, L., Marsh, E., Miller, I., Nabbout, R., Scheffer, I. E., Thiele, E. A., & Wright, S. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611618 · Cited by 1,711
Effect of Cannabidiol on Drop Seizures in the Lennox–Gastaut Syndrome
Devinsky, O., Patel, A. D., Cross, J. H., Villanueva, V., Wirrell, E. C., Privitera, M., Greenwood, S. M., Roberts, C., Checketts, D., VanLandingham, K. E., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714631 · Cited by 1,015
Thiele, E. A., Marsh, E. D., French, J. A., Mazurkiewicz-Beldzinska, M., Benbadis, S. R., Joshi, C., Lyons, P. D., Taylor, A., Roberts, C., Sommerville, K., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30136-3 · Cited by 905
Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial
Devinsky, O., Marsh, E., Friedman, D., Thiele, E., Laux, L., Sullivan, J., Miller, I., Flamini, R., Wilfong, A., Filloux, F., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00379-8 · Cited by 900
Haney, M., Malcolm, R. J., Babalonis, S., Nuzzo, P. A., Cooper, Z. D., Bedi, G., Gray, K. M., McRae-Clark, A., Lofwall, M. R., Sparenborg, S., et al. (2016) · Neuropsychopharmacology · doi:10.1038/npp.2015.367 · Cited by 206
Cited by
Cannabidiol Adverse Effects and Toxicity
Huestis, M. A., Solimini, R., Pichini, S., Pacifici, R., Carlier, J., & Busardò, F. P. (2019) · Current Neuropharmacology · doi:10.2174/1570159x17666190603171901 · Cited by 468
Freeman, T. P., Craft, S., Wilson, J., Stylianou, S., ElSohly, M., Di Forti, M., & Lynskey, M. T. (2021) · Addiction · doi:10.1111/add.15253 · Cited by 337
Cannabidiol: pharmacology and therapeutic targets
Britch, S. C., Babalonis, S., & Walsh, S. L. (2021) · Psychopharmacology · doi:10.1007/s00213-020-05712-8 · Cited by 307
Adverse effects of cannabidiol: a systematic review and meta-analysis of randomized clinical trials
Chesney, E., Oliver, D., Green, A., Sovi, S., Wilson, J., Englund, A., Freeman, T. P., & McGuire, P. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-020-0667-2 · Cited by 294
Cannabidiol for Pain Treatment: Focus on Pharmacology and Mechanism of Action
Mlost, J., Bryk, M., & Starowicz, K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228870 · Cited by 285
Metadata
- Authors
- Schoedel, K. A., Szeto, I., Setnik, B., Sellers, E. M., Levy-Cooperman, N., Mills, C., Etges, T., & Sommerville, K.
- Venue
- Epilepsy & Behavior
- Publisher
- Elsevier BV
- Published
- 2018-11
- Volume
- 88
- Pages
- 162-171
- ISSN
- 1525-5050 (ISSN-L)
- OpenAlex
- W2895399537
- Cited by
- 169
- References
- 5
- FWCI
- 8.93
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Abuse potential assessment of cannabidiol (CBD) in recreational polydrug users: A randomized, double-blind, controlled trial. https://app.cochat.ai/papers/10.1016/j.yebeh.2018.07.027
- The paper
- Schoedel, K. A., Szeto, I., Setnik, B., Sellers, E. M., Levy-Cooperman, N., Mills, C., Etges, T., & Sommerville, K. (2018). Abuse potential assessment of cannabidiol (CBD) in recreational polydrug users: A randomized, double-blind, controlled trial. Epilepsy & Behavior. https://doi.org/10.1016/j.yebeh.2018.07.027
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.